Comparison of Short-term Outcomes Between Faricimab and High-Dose Aflibercept in Patients With Neovascular Age-related Macular Degeneration - PubMed
6 hours ago
- #faricimab
- #aflibercept
- #age-related macular degeneration
- Study compares faricimab and high-dose aflibercept in treating neovascular age-related macular degeneration (nAMD).
- 62 patients (64 eyes) with nAMD and initial VA ≤20/25 were enrolled; 2 excluded, leaving 60 patients (62 eyes).
- Patients received 3 monthly loading doses of either 6.0 mg faricimab (IVF) or 8.0 mg high-dose aflibercept (IVHDA).
- BCVA and fluid changes were assessed at 4, 8, and 16 weeks compared to baseline.
- IVF group showed significant BCVA improvement at 16 weeks (P = .004), while IVHDA group improved at 8 and 16 weeks (P = .001 and P = .007).
- At 16 weeks, 90.3% of IVF and 80.6% of IVHDA patients achieved dry macula (P = .473).
- Both treatments improved BCVA, with IVHDA showing faster improvement, but IVF had higher dry macula rates.